v3.26.1
Acquisitions - Schedule of Assets Acquired and Liabilities Assumed (Details) - USD ($)
$ in Millions
1 Months Ended
Mar. 04, 2026
Jul. 25, 2025
Mar. 31, 2026
Ventyx Biosciences, Inc      
Business Combination [Line Items]      
Cash $ 120    
Acquired in-process research and development (IPR&D) 977    
Other assets and liabilities, net 81    
Acquisition date fair value of consideration transferred 1,178    
Less:      
Cash acquired (120)    
Cash paid, net of cash acquired $ 1,058   $ 1,100
Verve Therapeutics, Inc.      
Business Combination [Line Items]      
Cash   $ 389  
Acquired in-process research and development (IPR&D)   608  
Other assets and liabilities, net   166  
Acquisition date fair value of consideration transferred   1,163  
Less:      
Cash acquired   (389)  
Fair value of CVR liability   (177)  
Fair value of equity interest in Verve held before the business combination   (48)  
Cash paid, net of cash acquired   $ 549